Cargando…

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients

The objective of this study was to examine the maintenance of effect and safety after a hospital‐wide switch for economic reasons from adalimumab originator Humira® to biosimilar Amgevita® in real‐world rheumatoid arthritis (RA) patients and patient satisfaction with the switch. We conducted a singl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brouwer, Rianne, ten Klooster, Peter M., Masselink, Joost B., Vonkeman, Harald E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731312/ https://www.ncbi.nlm.nih.gov/pubmed/36479936 http://dx.doi.org/10.1002/prp2.1025

Ejemplares similares

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
por: Popescu, Claudiu Costinel, et al.
Publicado: (2022)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

The impact of health literacy: associations with disease activity and medication prescription in patients with rheumatoid arthritis
por: Gorter, Anne, et al.
Publicado: (2023)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Further evaluation of inflammatory and non-inflammatory aspects of pain in rheumatoid arthritis patients
por: Jansen, Niels, et al.
Publicado: (2023)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Validation and implementation of a patient-reported experience measure for patients with rheumatoid arthritis and spondyloarthritis in the Netherlands
por: Beckers, Esther, et al.
Publicado: (2020)

Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
por: Renton, William D., et al.
Publicado: (2019)

Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study
por: ten Klooster, P. M., et al.
Publicado: (2019)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis
por: Koop, Sanne M. W., et al.
Publicado: (2015)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Further Optimization of the Reliability of the 28-Joint Disease Activity Score in Patients with Early Rheumatoid Arthritis
por: Siemons, Liseth, et al.
Publicado: (2014)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
por: Burmester, Gerd R, et al.
Publicado: (2019)

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
por: Jani, Rajendrakumar H., et al.
Publicado: (2015)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis
por: Siemons, Liseth, et al.
Publicado: (2014)

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
por: Kay, Jonathan, et al.
Publicado: (2021)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
por: Cohen, Stanley, et al.
Publicado: (2017)

Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice
por: Versteeg, G. A., et al.
Publicado: (2018)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
por: Vernero, Marta, et al.
Publicado: (2023)

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
por: Bruni, Cosimo, et al.
Publicado: (2021)

Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
por: Steunebrink, Laura M. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ohhlb8p7oq1qng14rpr3588us2